BR112012017458A2 - uso de um agente de modificação de hormônio adrenal - Google Patents
uso de um agente de modificação de hormônio adrenalInfo
- Publication number
- BR112012017458A2 BR112012017458A2 BR112012017458A BR112012017458A BR112012017458A2 BR 112012017458 A2 BR112012017458 A2 BR 112012017458A2 BR 112012017458 A BR112012017458 A BR 112012017458A BR 112012017458 A BR112012017458 A BR 112012017458A BR 112012017458 A2 BR112012017458 A2 BR 112012017458A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen
- aryl
- modifying agent
- hormone
- halogen
- Prior art date
Links
- 239000005556 hormone Substances 0.000 title abstract 3
- 229940088597 hormone Drugs 0.000 title abstract 3
- 230000001919 adrenal effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002438 stress hormone Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
uso de um agente de modificação de hormônio adrenal a presente invenção refere-se a um método de tratamento de uma doença ou distúrbio caracterizado por níveis aumentados de hormônio de estresse e/ou níveis diminuídos de hormônio andrógeno em um indivíduo, compreendendo administrar ao indivíduo uma quantidades terapeuticamente efetiva de um composto representado pela fómula (l) em que n é 1 ou 3; r é hidrogênio ou --c(o)n(r~ a~)(r~ b~) em que r~ a~ e r~ b~ são independentemente --(c~1~-c~ 4~) alquila , ou --(c~ 1~-c~ 4~) alquila-(c~ 5~-c~ 7~) arila ,em que cada um de r~ a~ e r~ b~ é opcionalmente substituído por --(c~ 1~-c~ 4~) alcóxi; r~ 1~, r~ 2~ e r~ 3~ são independentemente hidrogênio, halogênio, ciano ou --(c~ 6~-c~ 10) arila, em que referida --(c~ 6~-c~ 10~) arila é opcionalmente substituída por halogênio, com a condição que não mais do que um de r~ 1~,r~ 2~ e r~ 3~ é hidrogênio; e r~ 4~ e r~ 5~ são hidrogênio ; ou um sal farmaceuticamente aceitável deste.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29498010P | 2010-01-14 | 2010-01-14 | |
| US61/294,980 | 2010-01-14 | ||
| PCT/US2011/021100 WO2011088188A1 (en) | 2010-01-14 | 2011-01-13 | Use of an adrenal hormone-modifying agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012017458A2 true BR112012017458A2 (pt) | 2017-12-19 |
| BR112012017458B1 BR112012017458B1 (pt) | 2020-10-20 |
Family
ID=43735742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012017458-4A BR112012017458B1 (pt) | 2010-01-14 | 2011-01-13 | Uso de di-hidrogeno fosfato de 4-[(5r)-6,7-di-hidro-5h-pirrolo[1,2-c]imidazol-5-il]-3- flurorbenzonitrila |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8609862B2 (pt) |
| EP (2) | EP3527208A1 (pt) |
| JP (4) | JP5602250B2 (pt) |
| KR (1) | KR101412206B1 (pt) |
| CN (2) | CN102711916B (pt) |
| AU (1) | AU2011205290C1 (pt) |
| BR (1) | BR112012017458B1 (pt) |
| CA (1) | CA2786443C (pt) |
| CL (1) | CL2012001961A1 (pt) |
| CY (2) | CY1121320T1 (pt) |
| DK (1) | DK2523731T3 (pt) |
| ES (1) | ES2707596T3 (pt) |
| HR (1) | HRP20190064T1 (pt) |
| HU (2) | HUE041967T2 (pt) |
| IL (1) | IL220804A0 (pt) |
| LT (2) | LT2523731T (pt) |
| LU (1) | LUC00159I2 (pt) |
| MA (1) | MA33904B1 (pt) |
| ME (1) | ME03371B (pt) |
| MX (2) | MX2012008212A (pt) |
| NL (1) | NL301043I2 (pt) |
| NO (1) | NO2020012I1 (pt) |
| NZ (1) | NZ601077A (pt) |
| PH (1) | PH12012501422B1 (pt) |
| PL (1) | PL2523731T3 (pt) |
| PT (1) | PT2523731T (pt) |
| RS (1) | RS58234B1 (pt) |
| SG (1) | SG182393A1 (pt) |
| SI (1) | SI2523731T1 (pt) |
| TN (1) | TN2012000352A1 (pt) |
| TR (1) | TR201900515T4 (pt) |
| WO (1) | WO2011088188A1 (pt) |
| ZA (1) | ZA201205058B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011205290C1 (en) * | 2010-01-14 | 2014-11-06 | Recordati Ag | Use of an adrenal hormone-modifying agent |
| JP2013528658A (ja) | 2010-06-16 | 2013-07-11 | エンベラ ニューロセラピューティクス，インコーポレイティド | 依存、精神疾患、及び神経変性病の治療のための組成物と方法 |
| AR086665A1 (es) | 2011-06-14 | 2014-01-15 | Lilly Co Eli | Inhibidor de aldosterona sintasa y composiciones farmaceuticas |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| WO2013043521A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| IN2014DN06781A (pt) * | 2012-01-17 | 2015-05-22 | Novartis Ag | |
| AU2013246908B2 (en) * | 2012-04-12 | 2016-06-30 | Novartis Ag | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
| EP2903615B1 (en) | 2012-10-05 | 2021-04-07 | Merck Sharp & Dohme Corp. | 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension |
| JP2015093832A (ja) * | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
| SI3166596T1 (sl) * | 2014-07-07 | 2018-10-30 | Novartis Ag | Farmacevtske odmerne oblike |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| HUE054248T2 (hu) | 2015-01-29 | 2021-08-30 | Recordati Ag | Eljárás kondenzált imidazo-származékok elõállítására |
| US20160287565A1 (en) | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| US20180185375A1 (en) * | 2015-06-22 | 2018-07-05 | Embera Neurotherapeutics, Inc. | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders |
| WO2018165649A1 (en) | 2017-03-10 | 2018-09-13 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5503843A (en) | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| US5658881A (en) | 1994-10-14 | 1997-08-19 | Twk, Inc. | Method for topical inhibition of the metabolic activity of cytochrome P450 |
| DE19814087A1 (de) * | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
| ATE457169T1 (de) | 1998-10-15 | 2010-02-15 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
| ES2275853T3 (es) * | 2001-02-16 | 2007-06-16 | Aventis Pharmaceuticals Inc. | Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3. |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| JP5138875B2 (ja) | 2005-07-19 | 2013-02-06 | 株式会社デンソー | センサ装置 |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| EP2007206A4 (en) | 2006-03-16 | 2010-12-08 | Yeda Res & Dev | METHOD AND COMPOSITION FOR THE PROTECTION OF NEURONAL TISSUE FROM DEGATES INDUCED BY HIGH LEVELS OF GLUTAMATE |
| RU2008150752A (ru) * | 2006-05-26 | 2010-07-10 | Новартис АГ (CH) | Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| KR20090055595A (ko) * | 2006-08-25 | 2009-06-02 | 노파르티스 아게 | 알도스테론 신타제 및/또는 11-베타-히드록실라제 및/또는 아로마타제에 의해 매개된 장애의 치료를 위한 융합 이미다졸 유도체 |
| EA200900812A1 (ru) * | 2006-12-18 | 2009-12-30 | Новартис Аг | Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы |
| EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| AU2011205290C1 (en) * | 2010-01-14 | 2014-11-06 | Recordati Ag | Use of an adrenal hormone-modifying agent |
| IN2014DN06781A (pt) * | 2012-01-17 | 2015-05-22 | Novartis Ag | |
| AU2013246908B2 (en) * | 2012-04-12 | 2016-06-30 | Novartis Ag | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
-
2011
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en not_active Ceased
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Active
- 2011-01-13 PH PH1/2012/501422A patent/PH12012501422B1/en unknown
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
-
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
-
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
-
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
-
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
-
2019
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
-
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501422B1 (en) | Use of an adrenal hormone-modifying agent | |
| MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
| NZ613370A (en) | Combinations for treating hcv | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| BR112016000975A8 (pt) | esteróides neuroativos, composições os compreendendo e uso dos mesmos | |
| BR112012000968B8 (pt) | composto, composição e método para inibir uma fosfatidil inositol-3 cinase. | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| MX392115B (es) | Composiciones que comprenden colina. | |
| BR112015000161A2 (pt) | composições de vetor de vírus adeno-associado modificado | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| MX355267B (es) | Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico. | |
| BR112012014729A2 (pt) | terapia combinada contra hcv | |
| BR112013004892A2 (pt) | composição de proteção de superfície sem fluoropolímero | |
| BR112012032462A2 (pt) | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. | |
| BR112015022538A2 (pt) | terapia de indução de rituximab seguida por terapia de acetato de glatirâmero | |
| MX355330B (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
| BR112013028095A2 (pt) | inibidores de csf-1r para o tratamento de tumores cerebrais | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| BR112017000519A2 (pt) | "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" | |
| EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: RECORDATI AG (CH) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2011, OBSERVADAS AS CONDICOES LEGAIS. |